211 related articles for article (PubMed ID: 20170407)
1. Using 17 α-hydroxyprogesterone caproate to impact rates of recurrent preterm delivery in clinical practice.
Rebarber A; Fox NS; Klauser CK; Istwan NB; Rhea DJ; Stanziano GJ; Saltzman DH
J Matern Fetal Neonatal Med; 2010 Oct; 23(10):1139-42. PubMed ID: 20170407
[TBL] [Abstract][Full Text] [Related]
2. Preterm birth prevention by 17 alpha-hydroxyprogesterone caproate vs. daily nursing surveillance.
Rittenberg C; Newman RB; Istwan NB; Rhea DJ; Stanziano GJ
J Reprod Med; 2009 Feb; 54(2):47-52. PubMed ID: 19301566
[TBL] [Abstract][Full Text] [Related]
3. Pregnancy outcomes of managed Medicaid members prescribed home administration of 17 α-hydroxyprogesterone caproate.
Lucas B; Poole-Yaeger A; Istwan N; Stanziano G; Rhea D; Mason M
Am J Perinatol; 2012 Aug; 29(7):489-96. PubMed ID: 22399213
[TBL] [Abstract][Full Text] [Related]
4. Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States.
Petrini JR; Callaghan WM; Klebanoff M; Green NS; Lackritz EM; Howse JL; Schwarz RH; Damus K
Obstet Gynecol; 2005 Feb; 105(2):267-72. PubMed ID: 15684150
[TBL] [Abstract][Full Text] [Related]
5. Pregnancy outcomes of women receiving compounded 17 α-hydroxyprogesterone caproate for prophylactic prevention of preterm birth 2004 to 2011.
Sibai BM; Istwan NB; Palmer B; Stanziano GJ
Am J Perinatol; 2012 Sep; 29(8):635-42. PubMed ID: 22576126
[TBL] [Abstract][Full Text] [Related]
6. The risk for preterm labor in women receiving 17 alpha-hydroxyprogesterone caproate prophylaxis for preterm birth prevention.
Joy S; Rhea DJ; Istwan NB; Desch CN; Stanziano G
Am J Perinatol; 2010 Apr; 27(4):343-8. PubMed ID: 20013580
[TBL] [Abstract][Full Text] [Related]
7. Increased recurrence of preterm delivery with early cessation of 17-alpha-hydroxyprogesterone caproate.
Rebarber A; Ferrara LA; Hanley ML; Istwan NB; Rhea DJ; Stanziano GJ; Saltzman DH
Am J Obstet Gynecol; 2007 Mar; 196(3):224.e1-4. PubMed ID: 17346529
[TBL] [Abstract][Full Text] [Related]
8. 17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study.
Nelson DB; McIntire DD; McDonald J; Gard J; Turrichi P; Leveno KJ
Am J Obstet Gynecol; 2017 Jun; 216(6):600.e1-600.e9. PubMed ID: 28223163
[TBL] [Abstract][Full Text] [Related]
9. Single dose 17 alpha-hydroxyprogesterone caproate in preterm labor: a randomized trial.
Tan PC; King AS; Vallikkannu N; Omar SZ
Arch Gynecol Obstet; 2012 Mar; 285(3):585-90. PubMed ID: 21796421
[TBL] [Abstract][Full Text] [Related]
10. 17 hydroxyprogesterone for the prevention of preterm delivery.
Meis PJ;
Obstet Gynecol; 2005 May; 105(5 Pt 1):1128-35. PubMed ID: 15863556
[TBL] [Abstract][Full Text] [Related]
11. 17alpha-hydroxyprogesterone caproate for the prevention of preterm delivery: A cost-effectiveness analysis.
Odibo AO; Stamilio DM; Macones GA; Polsky D
Obstet Gynecol; 2006 Sep; 108(3 Pt 1):492-9. PubMed ID: 16946206
[TBL] [Abstract][Full Text] [Related]
12. Progesterone does not prevent preterm births in women with twins.
Briery CM; Veillon EW; Klauser CK; Martin RW; Chauhan SP; Magann EF; Morrison JC
South Med J; 2009 Sep; 102(9):900-4. PubMed ID: 19668021
[TBL] [Abstract][Full Text] [Related]
13. Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial.
Rozenberg P; Chauveaud A; Deruelle P; Capelle M; Winer N; Desbrière R; Perrotin F; Bohec C; Connan L; Vayssière C; Langer B; Mantel A; Azimi S; Porcher R; Azria E;
Am J Obstet Gynecol; 2012 Mar; 206(3):206.e1-9. PubMed ID: 22381603
[TBL] [Abstract][Full Text] [Related]
14. Gestational age at initiation of 17-hydroxyprogesterone caproate (17P) and recurrent preterm delivery.
González-Quintero VH; Istwan NB; Rhea DJ; Smarkusky L; Hoffman MC; Stanziano GJ
J Matern Fetal Neonatal Med; 2007 Mar; 20(3):249-52. PubMed ID: 17437227
[TBL] [Abstract][Full Text] [Related]
15. Impact of 17P usage on NICU admissions in a managed medicaid population--a five-year review.
Mason MV; Poole-Yaeger A; Krueger CR; House KM; Lucas B
Manag Care; 2010 Feb; 19(2):46-52. PubMed ID: 20550052
[TBL] [Abstract][Full Text] [Related]
16. A randomized controlled trial of intramuscular versus vaginal progesterone for the prevention of recurrent preterm birth.
Elimian A; Smith K; Williams M; Knudtson E; Goodman JR; Escobedo MB
Int J Gynaecol Obstet; 2016 Aug; 134(2):169-72. PubMed ID: 27168167
[TBL] [Abstract][Full Text] [Related]
17. The impact of maternal body mass on the effectiveness of 17 alpha-hydroxyprogesterone caproate.
Ventolini G; Duke J; Po W; Barhan S; Rhea D; Desch C; Istwan N; Stanziano G
J Reprod Med; 2008 Sep; 53(9):667-71. PubMed ID: 18839818
[TBL] [Abstract][Full Text] [Related]
18. Prophylaxis with 17 alpha-hydroxyprogesterone caproate for prevention of recurrent preterm delivery: does gestational age at initiation of treatment matter?
How HY; Barton JR; Istwan NB; Rhea DJ; Stanziano GJ
Am J Obstet Gynecol; 2007 Sep; 197(3):260.e1-4. PubMed ID: 17826411
[TBL] [Abstract][Full Text] [Related]
19. Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial.
Caritis SN; Rouse DJ; Peaceman AM; Sciscione A; Momirova V; Spong CY; Iams JD; Wapner RJ; Varner M; Carpenter M; Lo J; Thorp J; Mercer BM; Sorokin Y; Harper M; Ramin S; Anderson G;
Obstet Gynecol; 2009 Feb; 113(2 Pt 1):285-92. PubMed ID: 19155896
[TBL] [Abstract][Full Text] [Related]
20. Influence of gestational age and reason for prior preterm birth on rates of recurrent preterm delivery.
Gonzalez-Quintero VH; Cordova YC; Istwan NB; Tudela F; Rhea DJ; Romary LM; Marimon A; Desch CN; Stanziano GJ
Am J Obstet Gynecol; 2011 Sep; 205(3):275.e1-5. PubMed ID: 22071063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]